Clinical Trials Directory

Trials / Completed

CompletedNCT00619073

PACT (Platelet Activity After Clopidogrel Termination)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
University of Massachusetts, Worcester · Academic / Other
Sex
All
Age
21 Years – 70 Years
Healthy volunteers
Accepted

Summary

Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after discontinuation of clopidogrel therapy is associated with an increased clotting risk. However, this theory has never been rigorously tested. The goal of this research is to determine whether discontinuation of clopidogrel results in increased platelet function.

Detailed description

In this study, we will address the question: does discontinuation of clopidogrel result in platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover study in normal subjects, in whom platelet reactivity will be measured before clopidogrel or placebo, during clopidogrel or placebo, and at various time points after discontinuation of clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75 mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of study assessment in both the clopidogrel arm and the placebo arm, because the clinically relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel result in platelet hyperreactivity?

Conditions

Interventions

TypeNameDescription
DRUGclopidogrel + aspirinClopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
DRUGplaceboPlacebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
DRUGAspirinAspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.

Timeline

Start date
2008-04-01
Primary completion
2009-05-01
Completion
2009-05-01
First posted
2008-02-20
Last updated
2018-05-31
Results posted
2012-11-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00619073. Inclusion in this directory is not an endorsement.